Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells
Breast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomateria...
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
PeerJ Inc.
2021-10-01
|
| Series: | PeerJ |
| Subjects: | |
| Online Access: | https://peerj.com/articles/12124.pdf |
| _version_ | 1797421840296050688 |
|---|---|
| author | Ana D. Pinzón-García Ruben Sinisterra Maria Cortes Fredy Mesa Sandra Ramírez-Clavijo |
| author_facet | Ana D. Pinzón-García Ruben Sinisterra Maria Cortes Fredy Mesa Sandra Ramírez-Clavijo |
| author_sort | Ana D. Pinzón-García |
| collection | DOAJ |
| description | Breast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done. |
| first_indexed | 2024-03-09T07:23:17Z |
| format | Article |
| id | doaj.art-ba5b9e6476b54dd7b97386d32f5d4f87 |
| institution | Directory Open Access Journal |
| issn | 2167-8359 |
| language | English |
| last_indexed | 2024-03-09T07:23:17Z |
| publishDate | 2021-10-01 |
| publisher | PeerJ Inc. |
| record_format | Article |
| series | PeerJ |
| spelling | doaj.art-ba5b9e6476b54dd7b97386d32f5d4f872023-12-03T07:13:25ZengPeerJ Inc.PeerJ2167-83592021-10-019e1212410.7717/peerj.12124Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cellsAna D. Pinzón-García0Ruben Sinisterra1Maria Cortes2Fredy Mesa3Sandra Ramírez-Clavijo4Chemistry Department, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilChemistry Department, Instituto de Ciências Exatas, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilRestorative Dentistry Department, Faculty of Dentistry, Universidade Federal de Minas Gerais, Belo Horizonte, BrazilFaculty of Natural Sciences, Department of Biology, Universidad del Rosario, Bogotá, ColombiaFaculty of Natural Sciences, Department of Biology, Universidad del Rosario, Bogotá, ColombiaBreast cancer is the second leading cause of death in women, and tamoxifen citrate (TMX) is accepted widely for the treatment of hormone receptor–positive breast cancers. Several local drug-delivery systems, including nanofibers, have been developed for antitumor treatment. Nanofibers are biomaterials that mimic the natural extracellular matrix, and they have been used as controlled release devices because they enable highly efficient drug loading. The purpose of the present study was to develop polycaprolactone (PCL) nanofibers incorporating TMX for use in the treatment of breast tumors. Pristine PCL and PCL-TMX nanofibers were produced by electrospinning and characterized physiochemically using different techniques. In addition, an in vitro study of TMX release from the nanofibers was performed. The PCL-TMX nanofibers showed sustained TMX release up to 14 h, releasing 100% of the TMX. The Resazurin reduction assay was used to evaluate the TMX cytotoxicity on MCF-7 breast cancer cell line and PBMCs human. The PCL-TMX nanofiber was cytotoxic toPBMCs and MCF-7. Based on these results, the PCL-TMX nanofibers developed have potential as an alternative for local chronic TMX use for breast cancer treatment, however tissue tests must be done.https://peerj.com/articles/12124.pdfTamoxifen citrateNanofibersPolycaprolactoneBreast cancer |
| spellingShingle | Ana D. Pinzón-García Ruben Sinisterra Maria Cortes Fredy Mesa Sandra Ramírez-Clavijo Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells PeerJ Tamoxifen citrate Nanofibers Polycaprolactone Breast cancer |
| title | Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
| title_full | Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
| title_fullStr | Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
| title_full_unstemmed | Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
| title_short | Polycaprolactone nanofibers as an adjuvant strategy for Tamoxifen release and their cytotoxicity on breast cancer cells |
| title_sort | polycaprolactone nanofibers as an adjuvant strategy for tamoxifen release and their cytotoxicity on breast cancer cells |
| topic | Tamoxifen citrate Nanofibers Polycaprolactone Breast cancer |
| url | https://peerj.com/articles/12124.pdf |
| work_keys_str_mv | AT anadpinzongarcia polycaprolactonenanofibersasanadjuvantstrategyfortamoxifenreleaseandtheircytotoxicityonbreastcancercells AT rubensinisterra polycaprolactonenanofibersasanadjuvantstrategyfortamoxifenreleaseandtheircytotoxicityonbreastcancercells AT mariacortes polycaprolactonenanofibersasanadjuvantstrategyfortamoxifenreleaseandtheircytotoxicityonbreastcancercells AT fredymesa polycaprolactonenanofibersasanadjuvantstrategyfortamoxifenreleaseandtheircytotoxicityonbreastcancercells AT sandraramirezclavijo polycaprolactonenanofibersasanadjuvantstrategyfortamoxifenreleaseandtheircytotoxicityonbreastcancercells |